Jiangsu Nhwa Pharmaceutical Co Ltd (002262) - Total Assets
Based on the latest financial reports, Jiangsu Nhwa Pharmaceutical Co Ltd (002262) holds total assets worth CN¥9.64 Billion CNY (≈ $1.41 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Jiangsu Nhwa Pharmaceutical Co Ltd cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Jiangsu Nhwa Pharmaceutical Co Ltd - Total Assets Trend (2005–2025)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Jiangsu Nhwa Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Jiangsu Nhwa Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Jiangsu Nhwa Pharmaceutical Co Ltd's total assets of CN¥9.64 Billion consist of 70.1% current assets and 29.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.7% |
| Accounts Receivable | CN¥1.47 Billion | 16.0% |
| Inventory | CN¥756.78 Million | 8.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥557.84 Million | 6.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Jiangsu Nhwa Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jiangsu Nhwa Pharmaceutical Co Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Nhwa Pharmaceutical Co Ltd's current assets represent 70.1% of total assets in 2025, an increase from 68.3% in 2005.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2025, up from 13.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 5.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 16.0% of total assets.
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangsu Nhwa Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Jiangsu Nhwa Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.69 | 5.50 | 6.60 |
| Quick Ratio | 5.12 | 4.94 | 5.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥5.67 Billion | CN¥5.32 Billion | CN¥3.01 Billion |
Jiangsu Nhwa Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu Nhwa Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.66 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | 9.3% |
| Total Assets | CN¥9.22 Billion |
| Market Capitalization | $2.84 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Nhwa Pharmaceutical Co Ltd's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jiangsu Nhwa Pharmaceutical Co Ltd's assets grew by 9.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jiangsu Nhwa Pharmaceutical Co Ltd (2005–2025)
The table below shows the annual total assets of Jiangsu Nhwa Pharmaceutical Co Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥9.22 Billion ≈ $1.35 Billion |
+9.28% |
| 2024-12-31 | CN¥8.44 Billion ≈ $1.24 Billion |
+15.17% |
| 2023-12-31 | CN¥7.33 Billion ≈ $1.07 Billion |
+13.07% |
| 2022-12-31 | CN¥6.48 Billion ≈ $948.40 Million |
+13.76% |
| 2021-12-31 | CN¥5.70 Billion ≈ $833.68 Million |
+18.39% |
| 2020-12-31 | CN¥4.81 Billion ≈ $704.17 Million |
+14.53% |
| 2019-12-31 | CN¥4.20 Billion ≈ $614.81 Million |
+4.18% |
| 2018-12-31 | CN¥4.03 Billion ≈ $590.13 Million |
+22.15% |
| 2017-12-31 | CN¥3.30 Billion ≈ $483.12 Million |
+10.98% |
| 2016-12-31 | CN¥2.97 Billion ≈ $435.32 Million |
+16.62% |
| 2015-12-31 | CN¥2.55 Billion ≈ $373.28 Million |
+32.68% |
| 2014-12-31 | CN¥1.92 Billion ≈ $281.35 Million |
+22.75% |
| 2013-12-31 | CN¥1.57 Billion ≈ $229.20 Million |
+16.47% |
| 2012-12-31 | CN¥1.34 Billion ≈ $196.79 Million |
+22.97% |
| 2011-12-31 | CN¥1.09 Billion ≈ $160.03 Million |
+14.60% |
| 2010-12-31 | CN¥954.30 Million ≈ $139.64 Million |
+22.24% |
| 2009-12-31 | CN¥780.68 Million ≈ $114.24 Million |
+7.03% |
| 2008-12-31 | CN¥729.41 Million ≈ $106.73 Million |
+22.22% |
| 2007-12-31 | CN¥596.78 Million ≈ $87.33 Million |
+18.34% |
| 2006-12-31 | CN¥504.30 Million ≈ $73.80 Million |
+4.44% |
| 2005-12-31 | CN¥482.86 Million ≈ $70.66 Million |
-- |
About Jiangsu Nhwa Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin… Read more